Get the Stockscreener App
3.48
2.96%
0.10
After Hours:
3.49
0.01
+0.29%
Perspective Therapeutics Inc stock is traded at $3.48, with a volume of 804.26K.
It is up +2.96% in the last 24 hours and down -12.56% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$3.38
Open:
$3.35
24h Volume:
804.26K
Relative Volume:
0.87
Market Cap:
$258.44M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-20.28
EPS:
-0.1716
Net Cash Flow:
$-37.99M
1W Performance:
+0.58%
1M Performance:
-12.56%
6M Performance:
+30.83%
1Y Performance:
-78.03%
1-Day Range:
$3.27
$3.49
1-Week Range:
$3.22
$3.49
52-Week Range:
$1.60
$16.02
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.48 | 239.87M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
133.73 | 225.15B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.71 | 155.92B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
383.34 | 146.41B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
94.03 | 118.42B | 34.20B | 4.69B | 5.30B | 3.63 |
|
EW
Edwards Lifesciences Corp
|
77.57 | 45.96B | 5.69B | 1.41B | 577.90M | 6.95 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
Published on: 2025-09-12 19:03:34 - Newser
Historical volatility pattern of Perspective Therapeutics Inc. visualizedJuly 2025 Earnings & Low Risk Entry Point Guides - Newser
Regression analysis insights on Perspective Therapeutics Inc. performance2025 Earnings Impact & AI Enhanced Trading Signals - Newser
Published on: 2025-09-12 17:12:08 - Newser
How hedge fund analytics apply to Perspective Therapeutics Inc. stockQuarterly Investment Review & Fast Moving Trade Plans - Newser
Perspective Therapeutics Inc. stock trend outlook and recovery pathWeekly Stock Summary & Consistent Profit Trade Alerts - Newser
Is a relief rally coming for Perspective Therapeutics Inc. holdersWeekly Risk Report & AI Powered Trade Plan Recommendations - Newser
Is Perspective Therapeutics Inc. reversing from oversold territoryBear Alert & Momentum Based Trading Ideas - Newser
Published on: 2025-09-12 03:50:21 - Newser
Analyzing net buyer seller activity in Perspective Therapeutics Inc.Trade Performance Summary & AI Powered Buy/Sell Recommendations - Newser
How to interpret RSI for Perspective Therapeutics Inc. stockJuly 2025 Movers & AI Based Buy and Sell Signals - Newser
Walleye Capital LLC Sells 436,402 Shares of Perspective Therapeutics, Inc. $CATX - MarketBeat
What institutional flow reveals about Perspective Therapeutics Inc.2025 Buyback Activity & Expert Verified Stock Movement Alerts - Newser
Published on: 2025-09-11 23:13:11 - Newser
Technical signs of recovery in Perspective Therapeutics Inc.July 2025 Levels & Weekly Return Optimization Alerts - Newser
Custom strategy builders for tracking Perspective Therapeutics Inc.Market Movement Recap & Long Hold Capital Preservation Plans - Newser
Perspective Therapeutics Inc.’s volatility index tracking explainedTrade Entry Report & Fast Exit and Entry Strategy Plans - Newser
Strategies to average down on Perspective Therapeutics Inc.July 2025 EndofMonth & Reliable Price Breakout Alerts - Newser
Published on: 2025-09-11 04:19:03 - Newser
B.Riley Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
Volume spikes in Perspective Therapeutics Inc. stock – what they meanMarket Volume Report & High Win Rate Trade Tips - Newser
What is B. Riley's Forecast for CATX Q3 Earnings? - MarketBeat
Chart based analysis of Perspective Therapeutics Inc. trends2025 Trading Recap & AI Forecasted Entry/Exit Points - Newser
What does recent volatility data suggest for Perspective Therapeutics Inc.2025 Performance Recap & Reliable Volume Spike Trade Alerts - Newser
Measuring Perspective Therapeutics Inc.’s beta against major indicesTrade Entry Summary & Precise Buy Zone Identification - Newser
What technical models suggest about Perspective Therapeutics Inc.’s comebackForecast Cut & Free Weekly Chart Analysis and Trade Guides - Newser
Can Perspective Therapeutics Inc. lead its sector in growthQuarterly Profit Summary & Reliable Breakout Forecasts - 뉴스영
Is Perspective Therapeutics Inc. Forming a Consolidation Base2025 Pullback Review & Free Daily Entry Point Trade Alerts - beatles.ru
Is Perspective Therapeutics Inc. stock entering bullish territoryJuly 2025 Intraday Action & Daily Profit Focused Screening - Newser
Does Perspective Therapeutics Inc. stock reflect fundamentals2025 Support & Resistance & Accurate Intraday Trade Tips - beatles.ru
Published on: 2025-09-07 23:03:44 - beatles.ru
B. Riley Research Analysts Lower Earnings Estimates for CATX - Defense World
Chart overlay techniques for tracking Perspective Therapeutics Inc.July 2025 Closing Moves & Fast Gain Stock Trading Tips - Newser
Leading vs lagging indicators on Perspective Therapeutics Inc. performanceJuly 2025 Weekly Recap & Reliable Intraday Trade Plans - Newser
How to use a screener to detect Perspective Therapeutics Inc. breakoutsJuly 2025 Summary & Real-Time Volume Analysis Alerts - Newser
Risk vs reward if holding onto Perspective Therapeutics Inc.Trade Performance Summary & Precise Buy Zone Tips - Newser
Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Can volume confirm reversal in Perspective Therapeutics Inc.2025 Major Catalysts & Pattern Based Trade Signal System - Newser
What indicators show strength in Perspective Therapeutics Inc.2025 EndofYear Setup & Safe Capital Investment Plans - Newser
Applying chart zones and confluence areas to Perspective Therapeutics Inc.July 2025 Analyst Calls & Community Verified Swing Trade Signals - Newser
Perspective Therapeutics Announces Chief Financial Officer Changes - MarketScreener
Perspective Therapeutics Names Joel Sendek as CFO - MarketScreener
Perspective Therapeutics Appoints Maya Martinez-Davis to Board - The Globe and Mail
Perspective Therapeutics Appoints Joel Sendek as CFO - TipRanks
Perspective Therapeutics' Strategic Leadership Shift: How CFO Joel Sendek Could Ignite Financial and Operational Momentum - AInvest
Perspective Therapeutics' Strategic Leadership Move and Its Implications for Biotech Growth - AInvest
Perspective Therapeutics Appoints Biotech Veteran Joel Sendek as Chief Financial Officer - GlobeNewswire
Former Wall Street All-Star Who Raised $2.5B: Perspective Therapeutics Lands Biotech Finance Veteran as CFO - Stock Titan
Smart tools for monitoring Perspective Therapeutics Inc.’s price actionEntry Point & Long-Term Safe Return Strategies - Newser
Aug EndMonth: Can Perspective Therapeutics Inc. deliver alphaJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - khodrobank.com
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
1.01%
Cap:
|
Volume (24h):